Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT01693068
Title	Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	EMD Serono
Indications	skin melanoma
Therapies	Dacarbazine Pimasertib
Age Groups:	adult
Covered Countries	USA \| SWE \| NZL \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CHE \| BEL \| AUS